Chemotherapy-induced anemia and thrombocytopenia occur in a large portion of patients receiving myelosuppressive chemotherapy, leading to therapy-related complications and to treatment delay/reduction/discontinuation that negatively influence patient survival. The development of effective supportive strategies for the treatment of chemotherapy-induced myelosuppression is therefore essential to improve the outcome of both conventional and targeted antineoplastic therapies.
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Statement of Translational Relevance (149 words)
Chemotherapy-induced anemia and thrombocytopenia occur in a large portion of patients receiving myelosuppressive chemotherapy, leading to therapy-related complications and to treatment delay/reduction/discontinuation that negatively influence patient survival. The development of effective supportive strategies for the treatment of chemotherapy-induced myelosuppression is therefore essential to improve the outcome of both conventional and targeted antineoplastic therapies.
Stem Cell Factor (SCF) is mainly used in second-line treatment regimens for mobilizationrefractory patients. Here we show that SCF protects the bone marrow from chemotherapy-induced damage and prevents the occurrence of anemia and thrombocytopenia in the peripheral blood of treated mice. We also show for the first time that the efficacy of SCF as a myeloprotective agent depends on the schedule of administration.
The observation that SCF is able to protect erythroid and megakaryocytic precursors in vivo provides a rationale for a future use of this cytokine to prevent drug-induced anemia and thrombocytopenia in cancer patients. 
Introduction
Chemotherapy-induced bone marrow damage results in anemia and thrombocytopenia that threaten the patients' quality of life and the overall efficacy of anticancer treatments. Hematopoietic growth factors such as erythropoietin and colony-stimulating factors are commonly used to promote hematopoietic recovery following chemotherapy but they cannot prevent the occurrence of druginduced myelosuppression. Stem Cell Factor (SCF) is produced by stromal cells of the bone marrow and binds the receptor c-kit expressed on hematopoietic stem and progenitor cells (1) . SCF is essential for erythroid homeostasis as mice defective for SCF or its receptor c-kit display severe macrocytic anemia and inefficient response to stress erythropoiesis (2) (3) (4) (5) (6) (7) . SCF administration has been demonstrated to stimulate hematopoiesis in rodents, primates and humans by increasing the number of bone marrow stem and progenitor cells (8) (9) (10) and to promote recovery after cytotoxic damage (11) . Besides stimulating hematopoietic cell expansion, SCF is a potent antiapoptotic factor for erythroid and megakaryocytic cells (12) (13) (14) (15) . In vitro, SCF is able to prevent chemotherapyinduced apoptosis of immature erythroblasts and megakaryocytes, which are exquisitely vulnerable to cytotoxic agents (14, 15) . In this report, we show that SCF acts as a myeloprotective agent in vivo, being able to protect bone marrow cells from cisplatin-induced damage. In particular, SCF protected bone marrow erythroid (TER119 + ) and megakaryocytic (CD41 + ) precursors from chemotherapy-induced depletion and prevented the occurrence of anemia and thrombocytopenia in the peripheral blood of chemotherapy-treated mice. Importantly, only an administration schedule that maintained a constant presence of SCF during and after chemotherapy treatment was able to prevent bone marrow damage and consequent anemia/thrombocytopenia, thus indicating the need for an uninterrupted delivery of survival stimuli in order to achieve effective myeloprotection.
Research. were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained with food and water ad libitum for the duration of the studies. Mice were treated as follows: the "Control" group received matched PBS injections, the "Cisplatin" group received a single intraperitoneal dose of 7,5 mg/Kg cisplatin (Sigma Aldrich, St. Louis, MO) at day 0, the "SCF" group received 50 μg/Kg recombinant murine SCF (mSCF; Peprotech, Rocky Hill, NJ) dissolved in PBS twice a day from day -1 to day 7, "Interrupted" mice received 7,5 mg/Kg cisplatin at day 0 and 100 μg/Kg mSCF at day -1 and once a day from day 1 to day 7 (being SCF treatment interrupted during cisplatin administration), "Constant" mice received cisplatin at day 0 and 50μg/Kg mSCF twice a day from day 0 to day 7 (covering also the day of cisplatin administration). SCF was administered subcutaneously.
Microscopy and flow cytometry
Bone marrow sections were prepared as follows: at the end of the treatment mice were sacrificed, femurs were removed, fixed in buffered paraformaldehyde 10% for 24 h, washed and exposed to decalcifying solution (EDTA 0.05M, NaOH 5 N). Samples were deparaffinized and hydrated and staining reactions were then performed on 6 µm-thick sections. To evaluate bone marrow cellularity, histological sections were stained with hematoxylin/eosin. TUNEL staining was 
Peripheral blood analyses
Peripheral blood was obtained from retroorbital bleeding of mice treated as described above.
Bleeding was performed at day 10 for hemoglobin analysis and at days 2+10 for platelet analysis.
Blood was dripped directly after removal into tubes containing 0.5M of EDTA. Analysis of peripheral blood parameters was conducted by a contract laboratory (AppiaLab, Rome, Italy) within two hours from bleeding. For hemoglobin and platelet evaluation, mice received two injections of cisplatin 5 mg/Kg at day 0 and day 4, which was necessary to produce a constant decrease in platelet number avoiding rebound effects that occur after a single chemotherapy treatment (16 
Results and discussion
To investigate whether SCF was able to protect bone marrow cells from chemotherapy-induced destruction in vivo, we induced myelosuppression in mice with a single dose of cisplatin and administered SCF according to two treatment schedules. In the cohort of mice indicated as "Interrupted", SCF was administered 24 hours before and 24 hours after cisplatin injection and once daily for 5 additional days. In the cohort of mice indicated as "Constant", SCF was administered 4 hours before and 4 hours after cisplatin injection and then twice a day for 6 additional days. In the "Constant" group the schedule of administration ensured a constant availability of SCF throughout the treatment period, considering that SCF has an elimination half-life of approximately 8 hours (17), whereas in the "Interrupted" group this condition was intentionally not fulfilled (Fig. 1) .
First we analyzed bone marrow sections from control mice (treated with PBS or with SCF alone) and mice treated with cisplatin (in the presence or in the absence of SCF delivered according to the schedules described above) stained with TUNEL to reveal the presence of apoptotic cells or with hematoxylin/eosin to display bone marrow structure. TUNEL-stained bone marrow sections showed a high number of apoptotic cells both in mice treated with cisplatin alone (36±6 per field) and in "Interrupted" mice (33±3), whereas in "Constant" mice the number of dying cells was significantly lower (9±2) (P<0.001) (Fig. 2A) . Upon hematoxylin/eosin staining the bone marrow of cisplatintreated mice showed a strong hypoplasia with myelofibrosis and clusters of dysplastic megakaryocytes (Fig. 2B, left panel, arrows) . The bone marrow of "Interrupted" mice was similar to that of mice treated with cisplatin alone, indicating that an intermittent administration of SCF compromises the ability of this cytokine to prevent bone marrow destruction (Fig. 2B, left) . These observations were confirmed by counting the absolute number of cells extracted from mouse femurs (Fig. 2B, right) . By contrast, bone marrow structure and cell numbers of "Constant" mice resembled those of mice treated with PBS, indicating that constant administration of SCF protects bone marrow cells from chemotherapy-induced damage. The analysis of May-Grünwald-Giemsa-stained cells extracted from femurs of mice treated as described above showed that megakaryocytes and erythroblasts were significantly more abundant in "Constant" mice as compared to mice treated with cisplatin alone (Fig. 3A) (P<0.001 and P<0.05 respectively).
An analysis of bone marrow cells of the granulocytic lineage on May-Grünwald-Giemsa-stained slides revealed a significant decrease of granulocytic precursors in the "Cisplatin" and in the "Interrupted" samples whereas SCF treatment restored the levels of immature granulocytes in the "Constant" group (data not shown). However, a massive presence of mature granulocytes in the "Cisplatin" and in the "Interrupted" samples (likely represented by the long-lived bone marrow (Fig. 4) . Similarly, an increased number of TER119 + bone marrow erythroid cells expressed Bcl-2 and Bcl-XL in "Constant" mice as compared to mice treated with cisplatin alone (Fig. 4) . In both cases, "Interrupted" mice did not differ significantly from mice treated with cisplatin alone. These results indicate that only a continuous stimulation with SCF is able to elicit antiapoptotic signals that act through the mitochondrial pathway, thus preventing the depletion of bone marrow erythroid and megakaryocytic cells.
Then, we wanted to investigate the consequences of SCF-induced myeloprotection on peripheral blood red cells and platelets. In order to obtain a sustained decrease of hemoglobin and platelets in the peripheral blood, mice were subjected to two injections of cisplatin respectively at day 0 and day 4 of treatment. Subsequent peripheral blood analyses revealed that at day 10 hemoglobin levels of "Constant" mice were significantly higher that those of cisplatin-treated animals (P<0.01) and similar to those of vehicle-treated controls, indicating that SCF efficiently prevented the occurrence of cisplatin-induced anemia (Fig. 5A ). An assessment of platelet levels showed a progressive decrease of platelet levels in the "Cisplatin" group and, at a lesser extent, in the "Interrupted" group (Fig. 5B) . Conversely, platelet levels of the "Constant" group, after an initial reduction started to increase and, ten days after the first chemotherapy insult, they reached the levels detected in control
Research. (Fig. 5B) were treated as follows: the "Control" group received matched PBS injections, the "Cisplatin" group received a single intraperitoneal dose of 7,5 mg/Kg cisplatin at day 0 (bolt), the "SCF" group subcutaneously received 50 μg/Kg recombinant murine SCF twice a day from day -1 to day 7, the "Interrupted" group received 7,5 mg/Kg cisplatin at day 0 (bolt) and 100 μg/Kg mSCF at day -1 and once a day from day 1 to day 7, the "Constant" group received cisplatin at day 0 (bolt) and 50 μg/Kg mSCF twice a day from day 0 to day 7. The experiment was repeated six times with groups of four mice each.
